Drive Therapeutics

Drive Therapeutics is a private, preclinical-stage biotech company developing next-generation aptamer therapeutics for major retinal diseases like wAMD and DME. The company leverages a proprietary aptamer platform designed to generate long-acting, highly specific ocular therapies that could offer improved efficacy and reduced dosing frequency compared to current anti-VEGF standards. With a founding team of industry veterans and backing from non-dilutive grants like an NSF SBIR Phase 1 award, Drive is positioned to advance its pipeline candidates. The company operates in a large market with significant unmet need, as a substantial portion of patients do not respond adequately to existing treatments.

Nucleic acid aptamer platform for developing long-acting, highly specific ocular therapeutics. Enables rapid development of ligands against novel targets and boasts a patent portfolio for retinal disease applications.

The retinal disease market is dominated by established anti-VEGF biologics (e.g., Eylea, Lucentis, Beovu) and newer long-acting agents like Vabysmo. Competitors are also developing gene therapies (e.g., RGX-314), sustained-release implants, and therapies targeting complementary pathways. Drive's differentiation lies in its aptamer platform's potential for long duration, novel target engagement, and combinatorial flexibility.